Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–12 of 12 results
Advanced filters: Author: "David Hunter" Clear advanced filters

  • Although paracetamol is widely used and recommended for the management of pain in osteoarthritis, accumulating data indicate that it lacks efficacy and is associated with severe adverse effects. A new meta-analysis adds further weight to calls for clinical practice and treatment guidelines to be updated to reflect the evidence.

    • David J. Hunter
    • Manuela L. Ferreira
    News & Views
    Nature Reviews Rheumatology
    Volume: 12, P: 320-321

  • Consistent with evidence from trials in osteoarthritis of the knee, the results of a randomized controlled trial demonstrate that, for symptomatic hip osteoarthritis, a single intra-articular injection of hyaluronic acid is no better than placebo at alleviating pain.

    • David J. Hunter
    News & Views
    Nature Reviews Rheumatology
    Volume: 5, P: 359-360

  • For patients with osteoarthritis, the current palliative approach of analgesic prescription followed by joint replacement is often inappropriate. Instead, care should be tailored to the needs of individuals and targeted towards the central complaints of pain and functional limitation. So why are we still getting it wrong?

    • David J. Hunter
    • Jocelyn L. Bowden
    News & Views
    Nature Reviews Rheumatology
    Volume: 13, P: 703-704

  • Important advances in 2014 foster new perspectives on definitions of early and end-stage disease, and promote a shift in the clinical management of osteoarthritis (OA) through implementing treatment algorithms intended to minimize strain on current health-care models. Collectively, these changes shed new light on developing and optimizing approaches to OA treatment.

    • Rebecca F. Moyer
    • David J. Hunter
    News & Views
    Nature Reviews Rheumatology
    Volume: 11, P: 65-66

  • Current therapeutic strategies for osteoarthritis (OA) are mostly palliative; modifying the structural progression of OA has, therefore, become a focus of drug development. This Review discusses the challenges involved in the discovery and development of disease-modifying OA drugs, and describes specific agents that have shown promise in phase II and III trials.

    • David J. Hunter
    Reviews
    Nature Reviews Rheumatology
    Volume: 7, P: 13-22

  • The success of genome wide association (GWA) studies raises the hope that disease-associated markers will be useful in predicting disease risk. However, the metrics used to report effect sizes in GWA studies are not useful for determining the accuracy of genetic profiles.

    • Peter Kraft
    • Sholom Wacholder
    • Stephen Chanock
    Reviews
    Nature Reviews Genetics
    Volume: 10, P: 264-269

  • Osteoarthritis (OA) is an important cause of disability worldwide, and its impact is growing rapidly. In this Opinion article, the authors draw attention to the current and projected burden of OA for individuals and for health-care systems, and call for a shift in the approach to the disease.

    • David J. Hunter
    • Deborah Schofield
    • Emily Callander
    Comments & Opinion
    Nature Reviews Rheumatology
    Volume: 10, P: 437-441